 Ramucirumab is a recombinant human monoclonal antibody and is used in the treatment of advanced malignancies.In childhood lymphoma, phase I and II studies have found a positive effect of using antibody therapy.Monoclonal antibodies used for autoimmune diseases include infliximab and adalimumab, which are effective in rheumatoid arthritis, Crohn's disease and ulcerative colitis by their ability to bind to and inhibit TNF-α.